Orchid Cellmark 'Actively Exploring Acquisitions' as ‘06 Reorg Gets Traction | GenomeWeb
NEW YORK (GenomeWeb News) — Orchid Cellmark is “actively exploring acquisition opportunities" as a reorganization begun in 2006 gains traction, CEO Thomas Bologna said in a statement.
Bologna made the remark in a statement disclosing the company’s fourth-quarter financial report, which included a 1.6-percent rise in revenue, a 25-percent decline in R&D spending, and a profit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.